80 related articles for article (PubMed ID: 10461006)
1. Clinical use of serum c-erbB-2 in patients with ovarian masses.
Cheung TH; Wong YF; Chung TK; Maimonis P; Chang AM
Gynecol Obstet Invest; 1999; 48(2):133-7. PubMed ID: 10461006
[TBL] [Abstract][Full Text] [Related]
2. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
[TBL] [Abstract][Full Text] [Related]
4. Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
Akcay T; Yasar O; Kuseyri MA; Dincer Y; Aydinli K; Benian A; Balcan E; Erenel H
Bratisl Lek Listy; 2016; 117(3):156-60. PubMed ID: 26925746
[TBL] [Abstract][Full Text] [Related]
5. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.
Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
[TBL] [Abstract][Full Text] [Related]
7. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
[TBL] [Abstract][Full Text] [Related]
8. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy.
Meden H; Marx D; Fattahi A; Rath W; Kron M; Wuttke W; Schauer A; Kuhn W
J Cancer Res Clin Oncol; 1994; 120(6):378-81. PubMed ID: 7908021
[TBL] [Abstract][Full Text] [Related]
11. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
12. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.
Seki A; Yoshinouchi M; Seki N; Kodama J; Miyagi Y; Kudo T
Int J Oncol; 2000 Jul; 17(1):103-6. PubMed ID: 10853025
[TBL] [Abstract][Full Text] [Related]
13. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
15. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
16. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses.
Antonić J; Rakar S
Anticancer Res; 1995; 15(4):1527-32. PubMed ID: 7654041
[TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
18. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients.
Yazici H; Dolapcioglu K; Buyru F; Dalay N
Cancer Invest; 2000; 18(2):110-4. PubMed ID: 10705872
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.
Van Calster B; Valentin L; Van Holsbeke C; Zhang J; Jurkovic D; Lissoni AA; Testa AC; Czekierdowski A; Fischerová D; Domali E; Van de Putte G; Vergote I; Van Huffel S; Bourne T; Timmerman D
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2420-8. PubMed ID: 21908724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
